Today, we are faced with a plethora of social issues such as an aging society, increasing lifestyle-related diseases, and soaring medical costs. However, due to the enormous cost, time, and effort involved in the development of new drugs, these issues are not being adequately addressed. This is because the conventional drug development methods using cultured cells, mice, and patient samples make it difficult to achieve an efficient drug discovery process. Instead, we use Drosophila (fruit flies), which is easy, fast, and inexpensive to raise and breed, has no ethical hurdles, and has similar genes and drug responses to mammals. We aim to develop a platform for Drosophila-based drug screening for identifying lead compounds for various diseases such as cancer, heart disease, stroke, rheumatism, and diabetes.
- M. Sonoshita, A. P. Scopton, P. M. U. Ung, M. A. Murray, L. Silber, A. Y. Maldonado, A. Real, A. Schlessinger, R. L. Cagan, and A. C. Dar, "A whole-animal platform to advance a clinical kinase inhibitor into new disease space", Nature Chemical Biology 14, 291 (2018)
- P. M. U. Ung, M. Sonoshita, A. P. Scopton, A. C. Dar, R. L. Cagan, and A. Schlessinger, "Integrated computational and Drosophila cancer model platform captures previously unappreciated chemicals perturbing a kinase network", PLOS Computational Biology 15, e1006878 (2019)
Drosophila-Based Drug Discovery
- Field leader: Jorgen Walker Peterson
- Funding: JST START, AMED Drug Discovery & Development
- Collaboration: Serendipity Lab, Masahiro Sonoshita (Hokkaido University), Tamiki Komatsuzaki (Hokkaido University), Ross Cagan (University of Glasgow)